1. Home
  2. CDIO vs SPHL Comparison

CDIO vs SPHL Comparison

Compare CDIO & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDIO
  • SPHL
  • Stock Information
  • Founded
  • CDIO 2017
  • SPHL 2002
  • Country
  • CDIO United States
  • SPHL Singapore
  • Employees
  • CDIO N/A
  • SPHL N/A
  • Industry
  • CDIO Biotechnology: Commercial Physical & Biological Resarch
  • SPHL Homebuilding
  • Sector
  • CDIO Health Care
  • SPHL Consumer Discretionary
  • Exchange
  • CDIO Nasdaq
  • SPHL Nasdaq
  • Market Cap
  • CDIO 6.4M
  • SPHL 6.0M
  • IPO Year
  • CDIO N/A
  • SPHL 2024
  • Fundamental
  • Price
  • CDIO $3.63
  • SPHL $0.50
  • Analyst Decision
  • CDIO Buy
  • SPHL
  • Analyst Count
  • CDIO 1
  • SPHL 0
  • Target Price
  • CDIO $60.00
  • SPHL N/A
  • AVG Volume (30 Days)
  • CDIO 41.9K
  • SPHL 99.3K
  • Earning Date
  • CDIO 08-14-2025
  • SPHL 02-21-2025
  • Dividend Yield
  • CDIO N/A
  • SPHL N/A
  • EPS Growth
  • CDIO N/A
  • SPHL N/A
  • EPS
  • CDIO N/A
  • SPHL N/A
  • Revenue
  • CDIO $19,507.00
  • SPHL $6,456,601.00
  • Revenue This Year
  • CDIO $1,434.82
  • SPHL N/A
  • Revenue Next Year
  • CDIO $4,661.91
  • SPHL N/A
  • P/E Ratio
  • CDIO N/A
  • SPHL N/A
  • Revenue Growth
  • CDIO N/A
  • SPHL N/A
  • 52 Week Low
  • CDIO $3.22
  • SPHL $0.35
  • 52 Week High
  • CDIO $53.10
  • SPHL $7.80
  • Technical
  • Relative Strength Index (RSI)
  • CDIO 41.96
  • SPHL N/A
  • Support Level
  • CDIO $3.58
  • SPHL N/A
  • Resistance Level
  • CDIO $4.05
  • SPHL N/A
  • Average True Range (ATR)
  • CDIO 0.33
  • SPHL 0.00
  • MACD
  • CDIO -0.01
  • SPHL 0.00
  • Stochastic Oscillator
  • CDIO 24.74
  • SPHL 0.00

About CDIO Cardio Diagnostics Holdings Inc. Common stock

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.

Share on Social Networks: